相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial
Alan K. Burnett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
Thomas Buechner et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype
Dimitri A. Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
Claude Gardin et al.
BLOOD (2007)
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission:: results of second randomization of the AML HD98-B treatment trial
RF Schlenk et al.
LEUKEMIA (2006)
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
U Hegenbart et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
S Amadori et al.
BLOOD (2005)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
EJ Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
JE Anderson et al.
BLOOD (2002)
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
RA Larson et al.
LEUKEMIA (2002)
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
AH Goldstone et al.
BLOOD (2001)
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
RM Stone et al.
BLOOD (2001)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia:: an Eastern Cooperative Oncology Group Trial (E5483)
C Robles et al.
LEUKEMIA (2000)
分享论文
